Studies comparing transplant vs no transplant in CLL
| Study . | Transplant . | No transplant . | Model . | Comments . |
|---|---|---|---|---|
| Kharfan-Dabaja et al28 | RIC allogenic | Conventional chemotherapy | ||
| NRM | 22% | 8% | Markov decision model | Are patient populations sufficiently similar? |
| ORR | 81% | 57% | ||
| Relapse death | 70% | 86% | ||
| Life expectancy | 35 mo | 25 mo | ||
| Herth et al29 | Donor | No donor | ||
| 2-y survival | 78% | 55% | Donor vs no donor comparison | Small numbers in no-donor group |
| Median survival | Not reached | 30.6 mo | ||
| Poon et al30 | Transplant | No transplant | ||
| 2-y survival | 64% | 25% | Consulted for transplant | Del(17p) group only; 2 groups not comparable |
| Study . | Transplant . | No transplant . | Model . | Comments . |
|---|---|---|---|---|
| Kharfan-Dabaja et al28 | RIC allogenic | Conventional chemotherapy | ||
| NRM | 22% | 8% | Markov decision model | Are patient populations sufficiently similar? |
| ORR | 81% | 57% | ||
| Relapse death | 70% | 86% | ||
| Life expectancy | 35 mo | 25 mo | ||
| Herth et al29 | Donor | No donor | ||
| 2-y survival | 78% | 55% | Donor vs no donor comparison | Small numbers in no-donor group |
| Median survival | Not reached | 30.6 mo | ||
| Poon et al30 | Transplant | No transplant | ||
| 2-y survival | 64% | 25% | Consulted for transplant | Del(17p) group only; 2 groups not comparable |
None of the studies listed are prospective randomized trials.